Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism

Neurology

Volumn 65, Issue 11, 2005, Pages 1820-1822

  Martignoni, E ^a,b   Cosentino, M ^c,f   Ferrari, M ^g   Porta, G ^c   Mattarucchi, E ^c   Marino, F ^c   Lecchini, S ^c   Nappi, G ^d,e  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f Section of Experimental and Clinical Pharmacology   (Italy)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; PRAMIPEXOLE; TOLCAPONE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; BENZOPHENONE DERIVATIVE; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; ENZYME INHIBITOR; GLUCURONIC ACID; NITROPHENOL; UDP-GLUCURONOSYLTRANSFERASE 1A9;

ADULT; AGED; ARTICLE; CASE REPORT; DISEASE PREDISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER DISEASE; LIVER TOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; UGT1A9 GENE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; FEMALE; GENOTYPE; GLUCURONIC ACIDS; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; LIVER DISEASES; MIDDLE AGED; MUTATION; NITROPHENOLS; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 33645094707     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000187066.81162.70     Document Type: Article

References (10)

1. Martignoni E, Blandini F, Pacchetti C, Nappi G. COMT inhibition and safety. Funct Neurol 2001;16 (suppl):135-140.
2. Nissinen E, Kaheinen P, Penttila KE, Kaivola J, Linden IB. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997;340:287-294.
3. Lautala P, Ethell BT, Taskinen J, Burchell B. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000;28:1385-1389.
4. Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Dis 2002;17:1362-1365.
5. Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993;21:81-92.
6. Jorga KM, Fotteler B, Heizmann P, Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 1999;48:513-520.
7. Yamanaka H, Nakajima M, Katoh M, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004;14:329-332.
8. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003;307:117-128.
9. Jinno H, Saeki M, Saito Y, et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003;306:688-693.
10. Smith KS, Smith PL, Heady TN, Trugman JM, Harman WD, Macdonald TL. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 2003;16:123-128.